Trials of ustekinumab biosimilars advance

Biosimilares/Novedades | Posted 29/05/2020 post-comment0 Post your comment

Japan-based Meiji Seika Pharma, together with the South Korean company Dong-A, have begun a phase I trial for their ustekinumab biosimilar. Meanwhile, the Australian firm NeuClone has reported results from the phase I trial of its ustekinumab biosimilar, NeuLara.

Clinical Trials 2 V13K29

Ustekinumab is a monoclonal antibody treatment for psoriasis and inflammatory bowel disease. The drug works by suppressing inflammatory cytokines (IL-12 and IL 23) so they cannot bind to their receptors. The originator product, Johnson & Johnson’s Stelara (ustekinumab), had worldwide sales of US$6.4 billion in 2019. The patents on Stelara will expire in the US in September 2023 and in Europe in January 2024 [1].

Various companies, including NeuClone [2], Formycon [3], Bio-Thera [4] and Alvotech [5] are working on a biosimilar of the drug.

Meiji Seika Pharma and Dong-A can now be added to that list, as they announced in December 2019 the start of a phase I clinical trial for their own ustekinumab biosimilar.

The trial is a randomized, double-blind, three-arm, single-dose study to compare the pharmacokinetics, safety and tolerability of the biosimilar (DMB 3115) with US and EU reference products. It is taking place at a single site in Europe in healthy volunteers.

The product has been manufactured by Korea-based DM Bio, a joint venture between Meiji Seika Pharma and Dong-A, which was established in 2011.

They may face strong competition to their biosimilar as German biosimilars company Formycon say they have already achieved ‘key milestones’ in the development of their biosimilar and expect to launch the drug once patents on Stelara have expired. Likewise, NeuClone began a large multi-site trial of their biosimilar in October 2019 [6], subject visits for which were completed in April 2020.

NeuClone announced in April 2020 that phase I patient monitoring and blood sampling has been completed for its ustekinumab biosimilar, NeuLara. So far, over 200 healthy volunteers have received a single dose of either NeuLara, or US- or EU-sourced reference product Stelara. Volunteers were monitored for up to 105 days, with blood samples collected for pharmacokinetics and anti-drug antibody testing.

Early analysis of the data suggests the compound is safe and tolerable. Dr Noelle Sunstrom, CEO and Founder of NeuClone, said in a statement: ‘We are delighted with the progress of NeuLara through its phase I clinical trial. Our attention now shifts to the final stages of development required for approval and supply of NeuLara to patients globally’.

The final clinical study report is anticipated in the third quarter of 2020.

Related articles
Bio-Thera launches first adalimumab copy biological in China

Japanese opportunity for biosimilars

EBE reveals Europe’s biosimilar pricing and reimbursement policies landscape

1. Derbyshire M. Patent expiry dates for biologicals: 2018 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2019;8(1):24-31. doi:10.5639/gabij.2019.0801.003 
2. GaBI Online - Generics and Biosimilars Initiative. NeuClone to start phase I trial for ustekinumab biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 May 29]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Phase I trials started for aflibercept and ustekinumab biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 May 29]. Available from:
4. GaBI Online - Generics and Biosimilars Initiative. Bio-Thera gains Chinese approval for adalimumab copy biological and starts ustekinumab trial []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 May 29]. Available from:
5. GaBI Online - Generics and Biosimilars Initiative. Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 May 29]. Available from:
6. GaBI Online - Generics and Biosimilars Initiative. NeuClone progress with ustekinumab and trastuzumab biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2020 May 29]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: Meiji Seika Pharma, NeuClone

comment icon Comments (0)
Post your comment
Related content
Canada approves adalimumab and bevacizumab biosimilars
Health Canada V13I20
Biosimilares/Novedades Posted 22/10/2021
Bioeq submits application for ranibizumab biosimilar to FDA
17696795_l edit
Biosimilares/Novedades Posted 15/10/2021
CuraTeQ submits application to EMA for pegfilgrastim biosimilar
Biosimilares/Novedades Posted 08/10/2021
EMA recommends approval of two adalimumab biosimilars
Biosimilares/Novedades Posted 01/10/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010